EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness Analysis of 68 Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma

J Rodriguez iD, G Martinez iD, S Mahase iD, M Roytman iD, A Haghdel iD, S Kim iD, G Madera, R Magge iD, P Pan iD, R Ramakrishna iD, T H Schwartz iD, S C Pannullo iD und 5 weitere

American Journal of Neuroradiology · 2023-07 · 44 (7) · 783-791

DOI: 10.3174/ajnr.a7901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Neuroradiology, online erschienen am 08.06.2023. Verfasst von J Rodriguez und 16 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Radiology (J.R., M.R., A.H., S.K., G. Madera, J.R.O., E.L., J.I.). Hauptthemen laut MEDLINE: Meningioma, Organometallic Compounds, Meningeal Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CTSC NIH, Novartis Pharmaceuticals Corporation, Radiological Society of North America.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND PURPOSE: While contrast-enhanced MR imaging is the criterion standard in meningioma diagnosis and treatment response assessment, gallium 68Ga-DOTATATE PET/MR imaging has increasingly demonstrated utility in meningioma diagnosis and management. Integrating 68Ga-DOTATATE PET/MR imaging in postsurgical radiation planning reduces the planning target volume and organ-at-risk dose. However, 68Ga-DOTATATE PET/MR imaging is not widely implemented in clinical practice due to higher perceived costs. Our study analyzes the cost-effectiveness of 68Ga-DOTATATE PET/MR imaging for postresection radiation therapy planning in patients with intermediate-risk meningioma. MATERIALS AND METHODS: We developed a decision-analytical model based on both recommended guidelines on meningioma management and our institutional experience. Markov models were implemented to estimate quality-adjusted life-years (QALY). Cost-effectiveness analyses with willingness-to-pay thresholds of $50,000/QALY and $100,000/QALY were performed from a societal perspective. Sensitivity analyses were conducted to validate the results. Model input values were based on published literature. RESULTS: The cost-effectiveness results demonstrated that 68Ga-DOTATATE PET/MR imaging yields higher QALY (5.47 versus 5.05) at a higher cost ($404,260 versus $395,535) compared with MR imaging alone. The incremental cost-effectiveness ratio analysis determined that 68Ga-DOTATATE PET/MR imaging is cost-effective at a willingness to pay of $50,000/QALY and $100,000/QALY. Furthermore, sensitivity analyses showed that 68Ga-DOTATATE PET/MR imaging is cost-effective at $50,000/QALY ($100,000/QALY) for specificity and sensitivity values above 76% (58%) and 53% (44%), respectively. CONCLUSIONS: 68Ga-DOTATATE PET/MR imaging as an adjunct imaging technique is cost-effective in postoperative treatment planning in patients with meningiomas. Most important, the model results show that the sensitivity and specificity cost-effective thresholds of 68Ga-DOTATATE PET/MR imaging could be attained in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaOrganometallic CompoundsMeningeal NeoplasmsHumansGallium RadioisotopesCost-Effectiveness AnalysisPositron-Emission TomographyMagnetic Resonance ImagingRadionuclide Imaging

Substanzen

copper dotatate CU-64Gallium RadioisotopesOrganometallic Compounds

Autor:innen und Institutionen

  • From the Department of Radiology (J.R., M.R., A.H., S.K., G. Madera, J.R.O., E.L., J.I.).
  • Siemens Healthineers (G. Martinez), Malvern, Pennsylvania.
  • Imaging Clinical Effectiveness and Outcomes Research Program (G. Martinez, P.C.S.), Health System Science, Feinstein Institutes for Medical Research, Manhasset, New York.
  • Department of Radiation Oncology (S.M.), Penn State Health, Mechanicsburg, Pennsylvania.
  • Brain Tumor Center, (R.M.).
  • Department of Neurology (P.P.), Columbia University Medical Center, New York, New York.

ORCID-Profile: J Rodriguez, G Martinez, S Mahase, M Roytman, A Haghdel, S Kim, R Magge, P Pan, R Ramakrishna, T H Schwartz, S C Pannullo, J R Osborne, E Lin, P C Sanelli, J Ivanidze

Förderung

  • CTSC NIH
  • Novartis Pharmaceuticals Corporation
  • Radiological Society of North America

Zitieren

APA

Rodriguez, J., Martinez, G., Mahase, S., Roytman, M., Haghdel, A., Kim, S., Madera, G., Magge, R., Pan, P., Ramakrishna, R., Schwartz, T. H., Pannullo, S. C., Osborne, J. R., Lin, E., Knisely, J. P. S., Sanelli, P. C., & Ivanidze, J. (2023). Cost-Effectiveness Analysis of 68 Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma. American Journal of Neuroradiology, 44(7), 783-791. https://doi.org/10.3174/ajnr.a7901

Vancouver

Rodriguez J, Martinez G, Mahase S, Roytman M, Haghdel A, Kim S, et al. Cost-Effectiveness Analysis of 68 Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma. American Journal of Neuroradiology. 2023;44(7):783-791. doi:10.3174/ajnr.a7901

BibTeX
@article{Rodriguez2023,
  author = {Rodriguez, J and Martinez, G and Mahase, S and Roytman, M and Haghdel, A and Kim, S and Madera, G and Magge, R and Pan, P and Ramakrishna, R and Schwartz, T H and Pannullo, S C and Osborne, J R and Lin, E and Knisely, J P S and Sanelli, P C and Ivanidze, J},
  title = {Cost-Effectiveness Analysis of 68 Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma},
  journal = {American Journal of Neuroradiology},
  year = {2023},
  volume = {44},
  number = {7},
  pages = {783--791},
  doi = {10.3174/ajnr.a7901}
}
Kostenlos starten →